Loading...
•
Sep 30, 2023
Ventyx Biosciences Q3 2023 Earnings Report
Ventyx Biosciences reported financial results for the third quarter of 2023 and highlighted recent corporate progress.
Key Takeaways
Ventyx Biosciences reported a net loss of $54.0 million for the third quarter of 2023, with cash, cash equivalents, and marketable securities totaling $300.8 million as of September 30, 2023. The company is focused on advancing its pipeline of oral therapies and expects to provide clinical updates in the first quarter of 2024.
Cash, cash equivalents and marketable securities were $300.8 million as of September 30, 2023.
Research and Development expenses were $49.8 million for the quarter ended September 30, 2023.
General and Administrative expenses were $8.2 million for the quarter ended September 30, 2023.
Net loss was $54.0 million for the quarter ended September 30, 2023.
Forward Guidance
Ventyx anticipates providing updates across its clinical-stage portfolio in the first quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...